Search
Changchun High-Tech Industries' Subsidiary BGI Biotech Receives Approval for Herpes Zoster Vaccine Clinical Trial
2025-06-04 /
Read about 0 minute
Author：小编
Changchun High-Tech Industries' subsidiary, BGI Biotech, has announced the approval of its clinical trial application for a recombinant herpes zoster vaccine (CHO cell) by the National Medical Products Administration. The vaccine, designed specifically for adults aged 40 and older, aims to prevent herpes zoster, commonly known as shingles. This milestone not only strengthens BGI Biotech's vaccine product line but also introduces additional options to the market, addressing an important public health need.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
